Press release
One "Target" for a Month: Creative Biolabs Features TNFRSF9
New York, USA - July 10, 2024 - The growing interest in TNFRSF9 (also known as CD137, 4-1BB) stems from its role as a co-stimulatory receptor on T cells, which can enhance immune responses against tumors. Research has shown that activating TNFRSF9 can significantly boost the efficacy of cancer immunotherapies. To synchronize with recent industry news highlighting the potential of TNFRSF9-targeted therapies to overcome the limitations of existing treatments and deliver durable anti-tumor responses, Creative Biolabs specifies their anti-TNFRSF9 engineered antibodies [https://www.creativebiolabs.net/symbolsearch_TNFRSF9_2.htm] in the monthly briefing.
Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg
I: Leading in with the Omnipresent Hi-Affi Trademark
"First of all, a short overview of our Hi-Affi Trademark platform to get you a clearer picture of our antibody performance," according to the scientist delivering the presentation, "which is a concert of advanced DNA technologies and powerful cell-free expression systems."
Almost all production work of recombinant antibodies [https://www.creativebiolabs.net/hi-affi-tm-recombinant-antibodies.htm] is run by the Hi-Affi Trademark platform, covering antibodies of different working modalities (blocking, neutralizing, etc.), antibodies against divergent targets (epitope-specific, mRNA encoded, etc.), and antibodies originated from different species (chicken, rabbit, etc.), with which the yielding reagents will be validated to have over 98% purity, high affinity, and reproducibility.
II: Catalog presentation
The scientist revealed a list of their research-use-only antibodies that are readily available for global delivery, and announced that the list is growing to cover more isotypes and more validated applications.
* Rat Anti-TNFRSF9 Recombinant Antibody
* Recombinant Mouse Anti-Human TNFRSF9 Antibody
* Hamster Anti-TNFRSF9 Recombinant Antibody
* Rat Anti-TNFRSF9 Recombinant Antibody
* Rat Anti-TNFRSF9 Recombinant Antibody
* Human Anti-TNFRSF9 Recombinant Antibody
* Human Anti-TNFRSF9 Recombinant Antibody
III: Case study: urelumab-a therapeutic breakthrough
Furthermore, a candidate that had received its final clinical results not a while ago was discussed-urelumab, an agonistic antibody targeting 4-1BB, making it a valuable tool in the fight against cancer. Two studies that evaluated urelumab in combination with cetuximab or nivolumab in patients with select, advanced solid tumors were reported in the paper.
"For relevant studies, we have anti-human 4-1BB recombinant antibodies [https://www.creativebiolabs.net/Anti-Human-4-1BB-Therapeutic-Antibody-Urelumab-13548.htm]," the scientist added, "which have been validated to be positive against native human antigen. Tested data are provided on the product page to help researchers know more about how they work in specific assays, like WB and ELISA."
IV: Outlook
Creative Biolabs prides itself on its commitment to innovation and collaboration and is poised to play a pivotal role in advancing TNFRSF9-targeted therapies.
"As the research community continues to explore the full potential of such critical factors in immunotherapy, we remain dedicated to driving scientific progress." The scientist summarized.
For more information about Creative Biolabs' TNFRSF9 antibodies and to explore their comprehensive product offerings, visit https://www.creativebiolabs.net or contact their expert team.
Company Overview
Creative Biolabs is a biotechnology company specializing in antibody development, engineering, and production. With a strong focus on innovation and customer service, Creative Biolabs provides a wide range of high-quality antibody products to support biomedical research and drug development worldwide.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email [http://www.universalpressrelease.com/?pr=one-target-for-a-month-creative-biolabs-features-tnfrsf9]
Phone: 1-631-830-6441
Country: United States
Website: https://www.creativebiolabs.net
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release One "Target" for a Month: Creative Biolabs Features TNFRSF9 here
News-ID: 3575212 • Views: …
More Releases from Getnews
Croatian Visionary Showcased Early Blueprint for Social Media Charity Entreprene …
Image: https://www.globalnewslines.com/uploads/2025/09/1758814645.jpg
"I recognized early that social media's real power wasn't just connecting people, but mobilizing them for causes," said Cukrov. "The technology existed to make charitable giving as simple as sharing a photo."
Cukrov developed comprehensive technical specifications for "My Facebook Wishlist," a donation platform concept that foresaw how social networks would transform charitable giving. His detailed proposal outlined features for medical emergencies, disaster relief, and educational fundraising that have since…
Geely Riddara Launches RD6 Econ All-electric Pickup in Southeast Asia
Geely Riddara launches the RD6 Econ all-electric pickup in Laos and the Philippines, with rollouts to Thailand, Malaysia, and Pakistan-Positioned as an economical, dual-use pickup for commercial and personal needs, the RD6 Econ combines outstanding cost efficiency with optimized energy consumption to offer global markets a more sustainable, value-driven choice.
Image: https://www.globalnewslines.com/uploads/2025/10/fdcbcbc3b86172a034fe204fc40717a4.jpg
The RD6 "Econ" designation derives from "Economic," reflecting the pickup's core values of being Eco-Friendly, Efficient and Economical. With the…
Lantana Recovery Announces Enhanced Norwalk Outreach to Strengthen Access to Car …
Image: https://www.globalnewslines.com/uploads/2025/10/1759424276.jpg
Lantana Recovery has enhanced operations at the Norwalk outreach office to improve coordination of intake and referrals to clinical programs based at the New Milford facility. The initiative reduces administrative friction and helps local residents gain clearer information about treatment options.
Local Access Point for Guidance and Coordination
The Norwalk outreach office serves as a local access point for intake coordination, insurance verification, and appointment scheduling. Staff explain treatment pathways and…
Crestline Roofing & Exteriors Denver Expands Roofing Services in Littleton, CO
Image: https://www.globalnewslines.com/uploads/2025/10/1759419153.jpg
Crestline Roofing & Exteriors Denver has announced the expansion of its professional roofing and exterior services to better serve residential and commercial properties throughout Littleton, CO. Known for its commitment to quality and reliability, the company continues to strengthen its reputation as a trusted provider of roofing solutions in the region.
The expansion comes as demand for dependable roofing continues to rise across Littleton, CO. With changing weather conditions placing…
More Releases for TNFRSF9
Tumor Necrosis Factor Receptor Superfamily Member 9: North America to Retain its …
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) pipeline Target constitutes close to 35 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes.
To evaluate factors influencing Tumor Necrosis Factor Receptor Superfamily Member 9, Market Research Hub (MRH) has included a report titled “Tumor Necrosis Factor Receptor…
